Cash, cash equivalents and marketable securities as of December 31, 2022, were $255.7M. As a result, we expect our current cash, cash equivalents and marketable securities will be sufficient to fund operating and capital expenditures into the second half of 2024.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GOSS:
- Gossamer Bio options imply 6.3% move in share price post-earnings
- Gossamer Bio options imply 36.4% move in share price post-earnings
- Gossamer Bio downgraded to Market Perform from Outperform at Raymond James
- Guggenheim starts Gossamer at Neutral after ‘underwhelming’ data
- Gossamer Bio initiated with a Neutral at Guggenheim
